First Turn Management LLC Sells 4,665 Shares of Revolution Medicines, Inc. $RVMD

First Turn Management LLC lowered its stake in shares of Revolution Medicines, Inc. (NASDAQ:RVMD) by 0.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 638,385 shares of the company’s stock after selling 4,665 shares during the period. Revolution Medicines accounts for approximately 5.8% of First Turn Management LLC’s portfolio, making the stock its 2nd biggest holding. First Turn Management LLC owned 0.33% of Revolution Medicines worth $50,847,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Global Retirement Partners LLC boosted its stake in Revolution Medicines by 1,002.8% in the 4th quarter. Global Retirement Partners LLC now owns 397 shares of the company’s stock worth $32,000 after buying an additional 361 shares during the last quarter. Indiana Trust & Investment Management Co acquired a new stake in Revolution Medicines in the 4th quarter worth about $32,000. Torren Management LLC acquired a new stake in Revolution Medicines in the 4th quarter worth about $33,000. Arax Advisory Partners acquired a new stake in Revolution Medicines in the 4th quarter worth about $38,000. Finally, Darwin Wealth Management LLC acquired a new stake in Revolution Medicines in the 4th quarter worth about $40,000. Institutional investors and hedge funds own 94.34% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on RVMD shares. Evercore reissued an “outperform” rating on shares of Revolution Medicines in a research note on Tuesday, April 14th. Sanford C. Bernstein started coverage on Revolution Medicines in a research note on Thursday, May 21st. They issued a “market perform” rating and a $151.00 price target on the stock. Truist Financial started coverage on Revolution Medicines in a research note on Monday, May 18th. They issued a “buy” rating and a $179.00 price target on the stock. UBS Group started coverage on Revolution Medicines in a research note on Friday, February 27th. They issued a “buy” rating on the stock. Finally, Oppenheimer raised their price target on Revolution Medicines from $165.00 to $195.00 and gave the stock an “outperform” rating in a research note on Monday, June 1st. Three investment analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $123.72.

Revolution Medicines Stock Performance

Revolution Medicines stock opened at $153.87 on Friday. The stock’s 50-day moving average is $140.76 and its 200-day moving average is $110.42. The company has a market cap of $32.71 billion, a price-to-earnings ratio of -21.76 and a beta of 1.40. The company has a debt-to-equity ratio of 0.19, a current ratio of 6.80 and a quick ratio of 6.80. Revolution Medicines, Inc. has a 12 month low of $34.00 and a 12 month high of $166.50.

Revolution Medicines (NASDAQ:RVMD) last released its quarterly earnings data on Wednesday, May 6th. The company reported ($2.29) EPS for the quarter, missing analysts’ consensus estimates of ($1.83) by ($0.46). During the same period in the prior year, the firm posted ($1.13) earnings per share. Equities analysts anticipate that Revolution Medicines, Inc. will post -7.94 earnings per share for the current year.

Insider Buying and Selling

In other news, insider Lin Wei sold 2,073 shares of the firm’s stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $99.48, for a total value of $206,222.04. Following the transaction, the insider directly owned 101,366 shares in the company, valued at $10,083,889.68. This trade represents a 2.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Jack Anders sold 2,753 shares of the firm’s stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $99.48, for a total value of $273,868.44. Following the completion of the transaction, the chief financial officer owned 125,512 shares in the company, valued at approximately $12,485,933.76. This trade represents a 2.15% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 148,592 shares of company stock worth $20,855,132. Corporate insiders own 7.60% of the company’s stock.

Revolution Medicines Company Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.